Mode
Text Size
Log in / Sign up
N/A N=260 Treatment

Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms

Aortic Aneurysm, Abdominal

Enrolled (actual)
260
Serious AEs
50.0%
Results posted
Jan 2018
Primary outcome: Primary: Freedom From Aneurysm-related Mortality (ARM) — .97 Proportion of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Talent Abdominal Stent Graft (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medtronic Cardiovascular
Primary completion
Jul 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Freedom From Aneurysm-related Mortality (ARM)
.97

Summary

The purpose of this study is to examine, through the endpoints established in this protocol, the long-term safety and effectiveness of the Talent Abdominal Stent Graft System, in a post-approval environment.

Eligibility Criteria

Inclusion Criteria

  • Subject must have an abdominal aortic aneurysm, with or without iliac involvement.
  • Iliac/femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories;
  • A proximal aortic neck length of ≥ 10mm;
  • Proximal aortic neck angulation ≤ 60°;
  • Distal iliac artery fixation length of ≥ 15mm;
  • An aortic neck diameter of 18-32mm and iliac artery diameters of 8-22mm; and
  • Vessel morphology suitable for endovascular repair.

Exclusion Criteria

  • Are less than 18 years of age
  • Are pregnant or lactating
  • Have a dominant patent inferior mesenteric artery and an occluded or stenotic celiac and/or superior mesenteric artery
  • Have aneurysmal involvement or occlusion (surgically performed or naturally occurring) of the bilateral internal iliac arteries
  • Have vessels and/or aneurysm dimensions that cannot accommodate the Talent Abdominal Stent Graft as per the indications in Section 3.
  • Have no distal vascular bed (one vessel lower extremity run-off required)
  • Have contraindications for use of contrast medium or anticoagulation drugs
  • Have an uncorrectable coagulopathy
  • Have an SVS/AAVS score greater than 2
  • Have a mycotic aneurysm
  • Have circumferential mural thrombus in the proximal aortic neck
  • Have had a recent (within 3 months) myocardial infarction (MI), cerebral vascular accident (CVA), or major surgical intervention
  • Have traumatic aortic injury
  • Have leaking, pending rupture or ruptured aneurysms
  • Have pseudoaneurysms resulting from previous graft placement
  • Require a revision to previously placed endovascular stent grafts.
  • Have genetic connective tissue disease (e.g., Marfan's or Ehlers-Danlos' Syndromes)
  • Have concomitant thoracic aortic or thoracoabdominal aneurysms
  • Are patients with active systemic infections
  • Are patients who have a condition that threatens to infect the graft.
  • Are patients with sensitivities or allergies to the device materials.
  • Have access vessels (as determined by treating physician) that preclude safe insertion of the delivery system. NOTE: Iliac conduits may be used to ensure the safe insertion of the delivery system.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00816062). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search